Vaccinating the inflammatory bowel disease patient

References

• Domm S, Cinatl J, Mrowietz U. The impact of treatment with tumour necrosis factor-alpha antagonists on the course of chronic viral infections: a review of the literature. Br J Dermatol 2008;159(6):1217-28
   PubMed Web of Science ®Google Scholar
• Keene JK, Lowe DK, Grosfeld JL, et al. Disseminated varicella complicating ulcerative colitis. JAMA 1978;239(1):45-6
   PubMed Web of Science ®Google Scholar
• Sands BE, Cuffari C, Katz J, et al. Guidelines for immunizations in patients with inflammatory bowel disease. Inflamm Bowel Dis 2004;10(5):677-92
   PubMed Web of Science ®Google Scholar
• Wasan SK, Baker SE, Skolnik PR, Farraye FA. A practical guide to vaccinating the inflammatory bowel disease patient. Am J Gastroenterol 2010;105(6):1231-8
   PubMed Web of Science ®Google Scholar
• Dezfoli S, Melmed GY. Vaccination issues in patients with inflammatory bowel disease receiving immunosuppression. Gastroenterol Hepatol (N Y) 2013;8(8):504-12
   Google Scholar
• Lu Y, Jacobson D, Bousvaros A. Immunizations in patients with inflammatory bowel disease. Inflamm Bowel Dis 2009;15(9):1417-23
   PubMed Web of Science ®Google Scholar
• Wasan SK, Calderwood AH, Long MD, et al. Immunization rates and vaccine beliefs among patients with inflammatory bowel disease: an opportunity for improvement. Inflamm Bowel Dis 2014;20(2):246-50
   PubMed Web of Science ®Google Scholar
• Crawford NW, Catto-Smith AG, Oliver MR, et al. An Australian audit of vaccination status in children and adolescents with inflammatory bowel disease. BMC Gastroenterol 2011;11:87
   PubMed Web of Science ®Google Scholar
• Wilckens V, Kannengiesser K, Hoxhold K, et al. The immunization status of patients with IBD is alarmingly poor before the introduction of specific guidelines. Scand J Gastroenterol 2011;46(7-8):855-61
   PubMed Web of Science ®Google Scholar
• Loras C, Saro C, Gonzalez-Huix F, et al. Prevalence and factors related to hepatitis B and C in inflammatory bowel disease patients in Spain: a nationwide, multicenter study. Am J Gastroenterol 2009;104(1):57-63
   PubMed Web of Science ®Google Scholar
• Melmed GY, Ippoliti AF, Papadakis KA, et al. Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses. Am J Gastroenterol 2006;101(8):1834-40
   PubMed Web of Science ®Google Scholar
• Wasan SK, Coukos JA, Farraye FA. Vaccinating the inflammatory bowel disease patient: deficiencies in gastroenterologists knowledge. Inflamm Bowel Dis 2011;17(12):2536-40
   PubMed Web of Science ®Google Scholar
• Carrera E, Manzano R, Garrido E. Efficacy of the vaccination in inflammatory bowel disease. World J Gastroenterol 2013;19(9):1349-53
   PubMed Web of Science ®Google Scholar
• Agarwal N, Ollington K, Kaneshiro M, et al. Are immunosuppressive medications associated with decreased responses to routine immunizations? a systematic review. Vaccine 2011;30(8):1413-24
   PubMed Web of Science ®Google Scholar
• Mamula P, Markowitz JE, Piccoli DA, et al. Immune response to influenza vaccine in pediatric patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2007;5(7):851-6
   PubMed Web of Science ®Google Scholar
• Hagihara Y, Ohfuji S, Watanabe K, et al. Infliximab and/or immunomodulators inhibit immune responses to trivalent influenza vaccination in adults with inflammatory bowel disease. J Crohns Colitis 2013;8(3):223-33
   PubMed Web of Science ®Google Scholar
• Altunoz ME, Senates E, Yesil A, et al. Patients with inflammatory bowel disease have a lower response rate to HBV vaccination compared to controls. Dig Dis Sci 2011;57(4):1039-44
   PubMed Web of Science ®Google Scholar
• Dotan I, Werner L, Vigodman S, et al. Normal response to vaccines in inflammatory bowel disease patients treated with thiopurines. Inflamm Bowel Dis 2011;18(2):261-8
   PubMed Web of Science ®Google Scholar
• Abdallah J, Kiran A, Tuyyab H, Jain A. Vaccination outcomes in inflammatory bowel disease. Presented at digestive disease week 2014, Chicago, Illinois, USA, 2014
   Google Scholar
• Battafarano DF, Battafarano NJ, Larsen L, et al. Antigen-specific antibody responses in lupus patients following immunization. Arthritis Rheum 1998;41(10):1828-34
   PubMed Web of Science ®Google Scholar
• Fields SW, Baiocco PJ, Korelitz BI. Influenza vaccinations: should they really be encouraged for IBD patients being treated with immunosuppressives? Inflamm Bowel Dis 2009;15(5):649-51. author reply 651-42
   PubMed Web of Science ®Google Scholar
• Kwon OS, Park YS, Choi JH, et al. [A case of ulcerative colitis relapsed by influenza vaccination]. Korean J Gastroenterol 2007;49(5):327-30
   PubMedGoogle Scholar
• Melmed GY. Vaccination strategies for patients with inflammatory bowel disease on immunomodulators and biologics. Inflamm Bowel Dis 2009;15(9):1410-16
   PubMed Web of Science ®Google Scholar
• Moscandrew M, Mahadevan U, Kane S. General health maintenance in IBD. Inflamm Bowel Dis 2009;15(9):1399-409
   PubMed Web of Science ®Google Scholar
• Rahier JF, Papay P, Salleron J, et al. H1N1 vaccines in a large observational cohort of patients with inflammatory bowel disease treated with immunomodulators and biological therapy. Gut 2011;60(4):456-62
   PubMed Web of Science ®Google Scholar
• Cullen G, Bader C, Korzenik JR, Sands BE. Serological response to the 2009 H1N1 influenza vaccination in patients with inflammatory bowel disease. Gut 2011;61(3):385-91
   PubMed Web of Science ®Google Scholar
• Advisory Committee on Immunization Practices. Recommended adult immunization schedule. United States, 2009*. Ann Intern Med 2009;150(1):40-4
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Advisory Committee on Immunization Practices (ACIP) recommended immunization schedules for persons aged 0 through 18 years and adults aged 19 years and older – United States, 2013. MMWR Surveill Summ 2013;62(Suppl 1):1
   Google Scholar
• Brogan MD, Shanahan F, Oliver M, et al. Defective memory B cell formation in patients with inflammatory bowel disease following tetanus toxoid booster immunization. J Clin Lab Immunol 1987;24(2):69-74
   PubMedGoogle Scholar
• Nielsen HJ, Mortensen T, Holten-Andersen M, et al. Increased levels of specific leukocyte- and platelet-derived substances during normal anti-tetanus antibody synthesis in patients with inactive Crohn disease. Scand J Gastroenterol 2001;36(3):265-9
   PubMed Web of Science ®Google Scholar
• Kane S. Abnormal Pap smears in inflammatory bowel disease. Inflamm Bowel Dis 2008;14(8):1158-60
   PubMed Web of Science ®Google Scholar
• Kane S, Khatibi B, Reddy D. Higher incidence of abnormal Pap smears in women with inflammatory bowel disease. Am J Gastroenterol 2008;103(3):631-6
   PubMed Web of Science ®Google Scholar
• Devon KM, Brown CJ, Burnstein M, McLeod RS. Cancer of the anus complicating perianal Crohn’s disease. Dis Colon Rectum 2009;52(2):211-16
   PubMed Web of Science ®Google Scholar
• Rahier JF, Ben-Horin S, Chowers Y, et al. European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 2009;3(2):47-91
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Recommendations on the use of quadrivalent human papillomavirus vaccine in males – Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep 2011;60(50):1705-8
   PubMedGoogle Scholar
• Jacobson DL, Bousvaros A, Ashworth L, et al. Immunogenicity and tolerability to human papillomavirus-like particle vaccine in girls and young women with inflammatory bowel disease. Inflamm Bowel Dis 2013;19(7):1441-9
   PubMed Web of Science ®Google Scholar
• Fiore AE, Uyeki TM, Broder K, et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep 2010;59(RR-8):1-62
   PubMedGoogle Scholar
• Narula N, Yamamura DL, Marshall JK. Should my patient with inflammatory bowel disease on immunosuppressive therapy be vaccinated against influenza virus? Can J Gastroenterol 2010;24(2):121-5
   PubMed Web of Science ®Google Scholar
• Lodhia N. The appropriate use of vaccines in patients with inflammatory bowel disease. J Clin Gastroenterol 2014;48(5):395-401
   PubMed Web of Science ®Google Scholar
• Boltin D, Gingold-Belfer R, Kimchi NA, et al. Utilization of influenza immunization in adults with Crohn’s disease-a longitudinal, population-based study. Inflamm Bowel Dis 2014;20(2):240-5
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2012;61(40):816-19
   PubMedGoogle Scholar
• Rahier JF, Magro F, Abreu C, et al. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 2014;8(6):443-68
   PubMed Web of Science ®Google Scholar
• Esteve M, Saro C, Gonzalez-Huix F, et al. Chronic hepatitis B reactivation following infliximab therapy in Crohn’s disease patients: need for primary prophylaxis. Gut 2004;53(9):1363-5
   PubMed Web of Science ®Google Scholar
• Montiel PM, Solis JA, Chirinos JA, et al. Hepatitis B virus reactivation during therapy with etanercept in an HBsAg-negative and anti-HBs-positive patient. Liver Int 2008;28(5):718-20
   PubMed Web of Science ®Google Scholar
• Shale MJ. The implications of anti-tumour necrosis factor therapy for viral infection in patients with inflammatory bowel disease. Br Med Bull 2009;92:61-77
   PubMed Web of Science ®Google Scholar
• Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009;50(3):661-2
   PubMed Web of Science ®Google Scholar
• Mast EE, Weinbaum CM, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep 2006;55(RR-16):1-33; quiz CE31-4
   Google Scholar
• Vida Perez L, Gomez Camacho F, Garcia Sanchez V, et al. [Adequate rate of response to hepatitis B virus vaccination in patients with inflammatory bowel disease]. Med Clin (Barc) 2009;132(9):331-5
   PubMed Web of Science ®Google Scholar
• Coates T, Wilson R, Patrick G, et al. Hepatitis B vaccines: assessment of the seroprotective efficacy of two recombinant DNA vaccines. Clin Ther 2001;23(3):392-403
   PubMed Web of Science ®Google Scholar
• Chevaux JB, Bigard MA, Bensenane M, et al. Inflammatory bowel disease and hepatitis B and C. Gastroenterol Clin Biol 2009;33(12):1082-93
   PubMedGoogle Scholar
• Gisbert JP, Villagrasa JR, Rodriguez-Nogueiras A, Chaparro M. Kinetics of anti-hepatitis B surface antigen titers after hepatitis B vaccination in patients with inflammatory bowel disease. Inflamm Bowel Dis 2013;19(3):554-8
   PubMed Web of Science ®Google Scholar
• Hepatitis B vaccines: WHO position paper – recommendations. Vaccine 2009;28(3):589-90
   PubMedGoogle Scholar
• Fonseca MO, Pang LW, de Paula Cavalheiro N, et al. Randomized trial of recombinant hepatitis B vaccine in HIV-infected adult patients comparing a standard dose to a double dose. Vaccine 2005;23(22):2902-8
   PubMed Web of Science ®Google Scholar
• Rey D, Krantz V, Partisani M, et al. Increasing the number of hepatitis B vaccine injections augments anti-HBs response rate in HIV-infected patients. Effects on HIV-1 viral load. Vaccine 2000;18(13):1161-5
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Villagrasa JR, Rodriguez-Nogueiras A, Chaparro M. Efficacy of hepatitis B vaccination and revaccination and factors impacting on response in patients with inflammatory bowel disease. Am J Gastroenterol 2012;107(10):1460-6
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Menchen L, Garcia-Sanchez V, et al. Comparison of the effectiveness of two protocols for vaccination (standard and double dosage) against hepatitis B virus in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2012;35(12):1379-85
   PubMed Web of Science ®Google Scholar
• Vogt TM, Wise ME, Bell BP, Finelli L. Declining hepatitis A mortality in the United States during the era of hepatitis A vaccination. J Infect Dis 2008;197(9):1282-8
   PubMed Web of Science ®Google Scholar
• Prevention of hepatitis A through active or passive immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1999;48(RR-12):1-37
   Google Scholar
• Bell BP, Shapiro CN, Alter MJ, et al. The diverse patterns of hepatitis A epidemiology in the United States-implications for vaccination strategies. J Infect Dis 1998;178(6):1579-84
   PubMed Web of Science ®Google Scholar
• Le C. Control of hepatitis A infection in the U.S. West J Med 1999;170(6):324
   PubMedGoogle Scholar
• Rosenthal P. Cost-effectiveness of hepatitis A vaccination in children, adolescents, and adults. Hepatology 2003;37(1):44-51
   PubMed Web of Science ®Google Scholar
• Cardell K, Akerlind B, Sallberg M, Fryden A. Excellent response rate to a double dose of the combined hepatitis A and B vaccine in previous nonresponders to hepatitis B vaccine. J Infect Dis 2008;198(3):299-304
   PubMed Web of Science ®Google Scholar
• Watson JC, Hadler SC, Dykewicz CA, et al. Measles, mumps, and rubella – vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1998;47(RR-8):1-57
   PubMedGoogle Scholar
• Harpaz R, Ortega-Sanchez IR, Seward JF. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008;57(RR-5):1-30. quiz CE32-4
   PubMedGoogle Scholar
• Wilkin T, Lee JY, Lensing SY, et al. Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men. J Infect Dis 2010;202(8):1246-53
   PubMed Web of Science ®Google Scholar
• Marin M, Guris D, Chaves SS, et al. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007;56(RR-4):1-40
   PubMedGoogle Scholar
• Colombel JF, Loftus EVJr, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn’s disease: the Mayo clinic experience in 500 patients. Gastroenterology 2004;126(1):19-31
   PubMed Web of Science ®Google Scholar
• Cullen G, Baden RP, Cheifetz AS. Varicella zoster virus infection in inflammatory bowel disease. Inflamm Bowel Dis 2012;18(12):2392-403
   PubMed Web of Science ®Google Scholar
• Farrell RJ, Shah SA, Lodhavia PJ, et al. Clinical experience with infliximab therapy in 100 patients with Crohn’s disease. Am J Gastroenterol 2000;95(12):3490-7
   PubMed Web of Science ®Google Scholar
• Leung VS, Nguyen MT, Bush TM. Disseminated primary varicella after initiation of infliximab for Crohn’s disease. Am J Gastroenterol 2004;99(12):2503-4
   PubMed Web of Science ®Google Scholar
• Ma C, Walters B, Fedorak RN. Varicella zoster meningitis complicating combined anti-tumor necrosis factor and corticosteroid therapy in Crohn’s disease. World J Gastroenterol 2013;19(21):3347-51
   PubMed Web of Science ®Google Scholar
• Ricart E, Panaccione R, Loftus EV, et al. Infliximab for Crohn’s disease in clinical practice at the Mayo clinic: the first 100 patients. Am J Gastroenterol 2001;96(3):722-9
   PubMed Web of Science ®Google Scholar
• Kopylov U, Levin A, Mendelson E, et al. Prior varicella zoster virus exposure in IBD patients treated by anti-TNFs and other immunomodulators: implications for serological testing and vaccination guidelines. Aliment Pharmacol Ther 2012;36(2):145-50
   PubMed Web of Science ®Google Scholar
• Kotton CN. Nailing down the shingles in IBD. Inflamm Bowel Dis 2007;13(9):1178-9
   PubMed Web of Science ®Google Scholar
• Singh A, Englund KQ. Who should receive the shingles vaccine? Cleve Clin J Med 2009;76(1):45-8
   PubMed Web of Science ®Google Scholar
• Gupta G, Lautenbach E, Lewis JD. Incidence and risk factors for herpes zoster among patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2006;4(12):1483-90
   PubMed Web of Science ®Google Scholar
• Marehbian J, Arrighi HM, Hass S, et al. Adverse events associated with common therapy regimens for moderate-to-severe Crohn’s disease. Am J Gastroenterol 2009;104(10):2524-33
   PubMed Web of Science ®Google Scholar
• Winthrop KL, Baddley JW, Chen L, et al. Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster. JAMA 2013;309(9):887-95
   PubMed Web of Science ®Google Scholar
• Moutsopoulos HM, Gallagher JD, Decker JL, Steinberg AD. Herpes zoster in patients with systemic lupus erythematosus. Arthritis Rheum 1978;21(7):798-802
   PubMed Web of Science ®Google Scholar
• Rubin LG, Levin MJ, Ljungman P, et al. 2013;IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 2014;58(3):309-18
   Web of Science ®Google Scholar
• Zhang J, Xie F, Delzell E, et al. Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA 2012;308(1):43-9
   PubMed Web of Science ®Google Scholar
• Zhang J, Delzell E, Xie F, et al. The use, safety, and effectiveness of herpes zoster vaccination in individuals with inflammatory and autoimmune diseases: a longitudinal observational study. Arthritis Res Ther 2011;13(5):R174
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Chaparro M. Vaccination strategies in patients with IBD. Nat Rev Gastroenterol Hepatol 2013;10(5):277-85
   PubMed Web of Science ®Google Scholar
• Dubinsky M, Abraham B, Mahadevan U. Management of the pregnant IBD patient. Inflamm Bowel Dis 2008;14(12):1736-50
   PubMed Web of Science ®Google Scholar
• Vasiliauskas EA, Church JA, Silverman N, et al. Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn. Clin Gastroenterol Hepatol 2006;4(10):1255-8
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Chaparro M. Safety of anti-TNF agents during pregnancy and breastfeeding in women with inflammatory bowel disease. Am J Gastroenterol 2013;108(9):1426-38
   PubMed Web of Science ®Google Scholar
• Zelinkova Z, de Haar C, de Ridder L, et al. High intra-uterine exposure to infliximab following maternal anti-TNF treatment during pregnancy. Aliment Pharmacol Ther 2011;33(9):1053-8
   PubMed Web of Science ®Google Scholar
• De Boer NK, Jarbandhan SV, de Graaf P, et al. Azathioprine use during pregnancy: unexpected intrauterine exposure to metabolites. Am J Gastroenterol 2006;101(6):1390-2
   PubMed Web of Science ®Google Scholar
• Christensen LA, Dahlerup JF, Nielsen MJ, et al. Azathioprine treatment during lactation. Aliment Pharmacol Ther 2008;28(10):1209-13
   PubMed Web of Science ®Google Scholar
• Gardiner SJ, Gearry RB, Roberts RL, et al. Exposure to thiopurine drugs through breast milk is low based on metabolite concentrations in mother-infant pairs. Br J Clin Pharmacol 2006;62(4):453-6
   PubMed Web of Science ®Google Scholar
• Sau A, Clarke S, Bass J, et al. Azathioprine and breastfeeding: is it safe? BJOG 2007;114(4):498-501
   PubMed Web of Science ®Google Scholar
• Centers for disease control and prevention. Travellers health. Available from: www.cdc.gov/travel
   Google Scholar
• Visser LG. The immunosuppressed. traveler. Infect Dis Clin North Am 2012;26(3):609-24
   PubMed Web of Science ®Google Scholar